MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

/PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the...

Related Keywords

South Africa ,Denmark ,Copenhagen ,Køavn ,United Kingdom ,Belgium ,Danish ,Lidia Oostvogels ,Groupb Streptococcal ,Drug Administration ,Boehringer Ingelheim ,Groupb Strep International ,Ghent University ,Groupb Streptococcus ,Lund University ,European Medicines Agency ,Groupb Strep ,Clinical Development ,Chief Medical Officer ,Senior Vice President ,Area Head ,Infectious Diseases ,Prophylactic Vaccines Curevac ,Vaccine Discovery ,Fast Track ,Priority Medicine ,Chief Executive Officer ,Groupb Strep Support ,Minervax ,